Alyeska Investment Group L.P. Sells 1,162,958 Shares of Bruker Corporation $BRKR

Key Points

• Alyeska Investment Group L.P. significantly reduced its stake in Bruker Corporation by selling 1,162,958 shares, resulting in ownership of just 325,000 shares, which represents a decrease of 78.2%.
• The company's latest earnings report showed a miss on EPS, with $0.32 reported compared to analysts' expectations of $0.33, alongside a slight year-over-year revenue decline of 0.4%.
• Bruker Corporation announced a quarterly dividend of $0.05 per share, which will be paid on October 3rd, representing an annualized dividend yield of 0.7%.

Alyeska Investment Group L.P. cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 78.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 325,000 shares of the medical research company's stock after selling 1,162,958 shares during the quarter. Alyeska Investment Group L.P. owned 0.21% of Bruker worth $13,566,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BRKR. Raymond James Financial Inc. purchased a new position in shares of Bruker in the fourth quarter worth $661,000. Northern Trust Corp increased its stake in shares of Bruker by 24.4% in the fourth quarter. Northern Trust Corp now owns 920,587 shares of the medical research company's stock worth $53,965,000 after buying an additional 180,448 shares during the period. Comerica Bank increased its stake in shares of Bruker by 2.0% in the fourth quarter. Comerica Bank now owns 36,866 shares of the medical research company's stock worth $2,161,000 after buying an additional 734 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Bruker in the fourth quarter worth $249,000. Finally, Ameriprise Financial Inc. increased its position in Bruker by 10.6% during the 4th quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after purchasing an additional 154,768 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on BRKR. Bank of America reduced their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Citigroup reduced their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, August 4th. Wells Fargo & Company reduced their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Finally, Barclays dropped their target price on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $51.30.

Bruker Stock Down 0.5%

Bruker stock traded down $0.17 during mid-day trading on Wednesday, reaching $31.02. The stock had a trading volume of 716,295 shares, compared to its average volume of 2,651,584. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of 59.96, a PEG ratio of 4.28 and a beta of 1.21. The company has a 50-day moving average price of $36.70 and a two-hundred day moving average price of $39.31. Bruker Corporation has a one year low of $28.53 and a one year high of $72.94. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business's revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker's dividend payout ratio is presently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.